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Abstract
Background: Fludarabine, is one of the most active single agents in the treatment of chronic lymphocytic
leukemia (CLL). Over time, however, virtually all CLL patients become fludarabine-refractory. To elucidate whether
microRNAs are involved in the development of fludarabine resistance, we analyzed the expression of 723 human
miRNAs before and 5-days after fludarabine mono-therapy in 17 CLL patients which were classified as responder or
refractory to fludarabine treatment based on NCI criteria.
Results: By comparing the expression profiles of these two groups of patients, we identified a microRNA signature
able to distinguish refractory from sensitive CLLs. The expression of some microRNAs was also able to predict
fludarabine resistance of 12 independent CLL patients. Among the identified microRNAs, miR-148a, miR-222 and
miR-21 exhibited a significantly higher expression in non-responder patients either before and after fludarabine
treatment. After performing messenger RNA expression profile of the same patients, the activation of p53-
responsive genes was detected in fludarabine responsive cases only, therefore suggesting a possible mechanism
linked to microRNA deregulation in non-responder patients. Importantly, inhibition of miR-21 and miR-222 by anti-
miRNA oligonucleotides induced a significant increase in caspase activity in fludarabine-treated p53-mutant MEG-
01 cells, suggesting that miR-21 and miR-222 up-regulation may be involved in the establishment of fludarabine
resistance.
Conclusions: This is the first report that reveals the existence of a microRNA profile that differentiate refractory and
sensitive CLLs, either before and after fludarabine mono-therapy. A p53 dysfunctional pathway emerged in
refractory CLLs and could contribute in explaining the observed miRNA profile. Moreover, this work indicates that
specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic
targets, therefore establishing an important starting point for future studies.
Background
Chronic Lymphocytic Leukemia (CLL) is the most com-
mon hematologic neoplasia in the Western world and is
characterized by a clonal expansion of CD5+ B-cells.
T h ed i s e a s em a yh a v eal o n ga n di n d o l e n tc o u r s e ,n o t
requiring treatment for years, or it may rapidly progress.
Initially most patients respond to purine nucleoside ana-
logs, which today represent pivotal agents for first and
second-line treatment [1]. However a significant fraction
of patients do not respond or become resistant to
fludarabine in the years [2] and prognosis for this group
of patients is poor [3]. The molecular mechanisms
underlying this process are not fully understood. It has
been reported that p53 dysfunction, deriving from
17p13 deletion, predicts non-response to fludarabine
therapy and poor prognosis [4,5]. Other genetic factors
associated with poor prognosis, such as del(11q22.3) [6]
and immunoglobulin (Ig) V(H) unmutated status [7],
have been also associated with shorter progression-free
survival after chemotherapy.
MicroRNAs (miRNAs) have been involved in the
regulation of many physiological and pathological
processes, through their wide action as post-transcrip-
tional gene expression modulators [8,9]. In CLL, miR-
15/16 were shown to be located within 13q14
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pressor genes [11], possibly through the modulation of
BCL2 [12] and various other target genes [13]. A
germline mutation affecting miRNA maturation was
detected in few cases of familial CLL as well as in the
New Zealand Black (NZB) mouse strain, a mice devel-
oping a B lymphoproliferative disease that is a model
for human CLL [14,15]. A set of miRNAs was able to
distinguish CLLs from normal CD5+ B-cells [16] and
13 miRNAs associated to CLL prognostic groups were
identified [17] through the identification of the mole-
cular profiles of CLLs with IgVH mutated or unmu-
tated status combined with ZAP70 levels. Likewise,
m i R - 2 9 ca n dm i R - 2 2 3h a v eb e e nu s e dt oc r e a t ea
quantitative PCR-based score able to improve CLL
patients stratification in terms of treatment free survi-
val and overall survival, when combined with two
other prognostic factors [18].
Recently, Zenz and colleagues found that fludarabine-
refractory CLLs were characterized more frequently
(53%) by lower levels of miR-34a than sensitive CLLs
(9%) [19]. MiR-34a has been implicated in CLL response
to DNA damage through a p53-mediated induction,
while miR-106b has been linked to Itch inhibition, and
consequent p73 activation, in deacetylase inhibitors
treated CLLs [20].
Fludarabine is an active agent in CLL and, it is fre-
quently used nowadays in combination regimens in
first and second line treatment, especially in younger
and fit patients. Fludarabine as single agent produces
better response rates than chlorambucil and represents
ar e a s o n a b l ec h o i c ea ss i n g l ea g e n ti nf r a i lo re l d e r l y
patients [21]. Because specific miRNAs may be
involved in patients response to fludarabine treatment
and in the development of fludarabine resistance, we
designed this study aimed at identifying the miRNA
expression profile associated with the response to flu-
darabine, used as a single agent, in the treatment of
patients with CLL.
Results
To investigate the possible involvement of miRNAs in
fludarabine resistance, we analyzed the miRNA expres-
sion profile of 17 CLL patients, before and after 5 days
of treatment with fludarabine as single agent. Based on
NCI criteria, 9 of the patients exhibited a clinical
response (CR), i.e. they attained either complete or par-
tial response, while 8 patients were resistant to the treat-
ment and were classified as non responders (NR).
Characteristics of the enrolled patients are shown in
Table 1. An additional blind cohort of 12 patients was
recruited among patients who were treated with fludara-
bine (Table 1), to test the efficacy of specific miRNAs as
response predictors.
Fludarabine induces a modulation of miRNA expression
that exhibits a differential expression between responder
and non-responder patients
We evaluated the miRNAs expression in 33 samples
obtained from CLL patients before and after treatment,
hereafter called pre and post, through the hybridization
on a miRNA platform (Agilent technologies) able to
assess the expression levels of 723 human miRNAs
(MiRBASE release 10.1). First, we identified the miR-
NAs induced or repressed by fludarabine treatment by
comparing post CLLs to the pre-treatment samples
(fold change >1.5 and p-value < 0.05). We compared
pre and post samples in the entire groups or in the
NR and CR sub-groups separately, which revealed 97,
67 and 60 differentially expressed miRNAs, respec-
tively. Among these, using Venn Diagram intersection,
we identified 37 miRNAs that were differentially
expressed either in the CR cohort and in the NR
cohort of samples (Additional file 1: Table S1 and
Additional file 2: Table S2). A hierarchical clustering
algorithm, performed using the list of 37 miRNAs, cor-
rectly classified the pre versus post fludarabine samples
(Figure 1). The complete list of miRNAs that were
identified as differentially expressed either in the CR
cohort or in the NR cohort of samples or both can be
found in Additional file 2: Table S2.
The post versus pre treatment analysis revealed that 37
miRNAs were similarly modulated by fludarabine in
both NR and CR patients. This set of miRNAs indi-
cated common mechanisms modulated by fludarabine,
but could not reveal mechanisms underlying resistance
to treatment. However, many additional miRNAs
exhibited a different modulation in CRs versus NRs,
which could be used to derive a miRNA signature
associated with fludarabine resistance. To investigate
this hypothesis, we searched for miRNAs whose
expression was significantly different between these
two cohorts of CLL patients. Analyses of pre and post
treatment samples were performed separately. The lists
of differentially expressed miRNAs were obtained by
statistical analysis of microarray data (Table 2 and 3).
The comparison of CR and NR patients led to the
identification of 10 differentially expressed miRNAs in
the pre-treatment setting (p < 0.05), listed in Table 2.
This set of miRNAs was used to classify the patients
by a clusterization algorithm. Eighty-two percent of
patients were correctly classified by a cluster analysis
(all but three: CLL 11, 18 and 22) (Figure 2A). The
comparison of CRs and NRs in the post-treatment set-
ting led to the identification of 11 miRNAs differen-
tially expressed between resistant and sensitive patients
(p < 0.05) (Table 3). Cluster analysis of these miRNAs
was able to correctly classify 88% samples (all but two:
CLL 4 and 22) (Figure 2B).
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222 and miR-148a by quantitative reverse-transcription
PCR (RT-qPCR) on the same group of 16 post samples,
adding also 3 new samples. We chose these miRNAs
considering the extent of their modulation and because
t h e ya r ed i f f e r e n t i a l l ye x p r e s s e db o t hb e f o r ea n da f t e r
the treatment. The expression level of every miRNA in
every post CLL was assayed in triplicate and normalized
on U6 RNA expression levels. Microarray results were
confirmed by RT-qPCR in every group of CLLs (Addi-
tional file 3: Figure S1).
Prediction of Fludarabine resistance in an independent
cohort of patients
To verify whether the three validated miRNAs (miR-
21, miR-148a and miR-222) might be able to predict
the efficacy of fludarabine treatment and might there-
fore become useful in directing patients therapy, we
collected a new cohort of 12 patients (test set). These
patients were treated by fludarabine as single agent
because of disease progression. Samples were collected
immediately before the treatment and the miRNA
expression was assayed by RT-qPCR. In this new
cohort, results were even more clear than in the
microarray training set of samples (Figure 3A). Patients
classified as NRs displayed a significantly (p < 0.05 at
two-tailed t-test) increased expression of miR-21, miR-
148a and miR-222 if compared to patients sensitive to
treatment. Interestingly, we were also able to predict
the response to treatment of newly diagnosed patients
by using a score based on the combination of miR-21,
148a and 222 expression levels. Using this score based
on quantitative expression of 3 miRNAs, prediction
was 100% accurate (Figure 3B).
Genes modulated by fludarabine in sensitive -but not
refractory- CLLs are induced by p53
To better elucidate the molecular context responsible
for the differential expression of miRNAs in NR versus
CR patients, we performed a mRNA expression profile
on a subgroup of the samples. Experiments data were
obtained for pre and post fludarabine treatment of 14
patients (the same employed for miRNA analysis, except
CLL-04, CLL-09 and CLL-16A, whose RNA was not
available), 7 of them were CRs and 7 NRs. We hybri-
dized the samples on a human mRNA platform (Agilent
Technologies) able to assess the expression levels 41,000
human transcripts. We performed an analysis aimed at
identifying the genes induced or repressed by the phar-
macologic treatment, with a particular interest in genes
modulated only in CRs or NRs. To this end, we normal-
ized the expression of every gene in each post sample to
the expression of the same gene in the matched pre
sample. We identified the mRNAs that exhibited a sig-
nificant differential modulation (p-value < 0.05) after
fludarabine treatment, separately analyzing refractory
and sensitive CLLs (data not shown). Then, we identi-
fied the most significant pathways modulated by fludara-
bine through a Pathway Enrichment analysis of the two
gene lists. Interestingly, the p53 pathway emerged as the
most significantly induced pathway in the cohort of CR
patients (Table 4). For example, G1/S and G2/M DNA
damage checkpoints, p53 stabilization and p53-depen-
dent response, BH3-only proteins pathways were all sig-
nificantly enriched in the CR cohort of CLL patients.
Conversely, the same pathways were not enriched or
were less significant in NR patients, indicating that NR
CLLs had a dysfunctional p53 pathway. A pathway
representative of p53 cell cycle control was generated,
Table 1 Characteristics of the patients
Training set Test set
Not Responder
group
Complete Responder
group
Not Responder
group
Complete Responder
group
n=8 n=9 n=5 n=7
Male, n(%) 7 (87.5%) 6 (66.6%) 4 (80%) 2 (28.6%)
Female, n(%) 1 (12.5%) 3 (33.3%) 1 (20%) 5 (71.4%)
Median age at diagnosis, years
(range)
67,5 (35-80) 66 (40-85) 68 (61-76) 60 (37-78)
11qdel, n(%) 0 (0%) 2 (22.2%) 0 (0%) 0 (0%)
17pdel, n(%) 2 (25%) 1 (11.1%) 3 (60%) 0 (0%)
Previous lines of therapy, n (%)
(clorambucil)
8 (100%) 5 (55.5%) 4 (80%) 3 (42.9%)
Rai Stage, n (%)
0-I 7 (87.5%) 9 (100%) 2 (40%) 4 (57.1%)
II-IV 1 (12.5%) 0 (0%) 3 (60%) 3 (42.9%)
Time to Treatment (months) 35.6 (0-75) 17.0 (0-56) 7.7 (0-20) 32.2 (10-75)
Ferracin et al. Molecular Cancer 2010, 9:123
http://www.molecular-cancer.com/content/9/1/123
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NR groups (Figure 4A), while the average expression
level of all the genes involved in p53 pathway is graphi-
cally represented in Figure 4B.
Inhibition of miR-21 and miR-222 increases caspase
activity after fludarabine treatment
The above results suggest that an abnormal miRNA
e x p r e s s i o nm a yb ei n v o l v e di nt h eg e n e r a t i o no f
fludarabine resistance. Among the various miRNAs dif-
ferentially expressed between NR versus CR patients,
miR-21, miR-222 and miR-148a emerged as significantly
up-regulated in two different cohorts of refractory
patients, both before and after fludarabine administra-
tion. MiR-21 has a well-established role in protection
from apoptosis and drug-response modulation [22] and
miR-222 is an important cell cycle regulator through its
action on p27 [23,24]. We therefore investigated
Figure 1 MiRNAs modulated by fludarabine. Cluster analysis of 17 CLL patients based on 37 miRNAs differentially expressed pre and post
fludarabine treatment. Statistical analysis revealed that 37 miRNAs are modulated by the drug both in sensitive (CR) and refractory (NR) patients.
The expression values of the genes represented on the heatmap correspond to the values normalized on miRNA mean expression across all
samples. CLL pre treatment are colored in blue, post treatment in red.
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death activity in the human MEG-01 cell model. We
employed the MEG-01 cell line because it carries a
13q14 deletion affecting miR-15a/miR-16-1, typical of
CLL, and a mutant TP53 gene. MiR-16 is indeed down-
regulated (fold-change 2.3, p = 0.07) in pre-treatment
fludarabine-refractory CLLs, and, as above indicated,
NRs are defective in the p53 pathway. These cells may
therefore mimic features which are responsible for resis-
tance to fludarabine. We hypothesized that anti-miR-21,
148a and 222 could be implicated in fludarabine-
induced apoptotic process. We therefore assayed the
MEG-01 cells for Caspase 3/7 activation (Caspase 3/7
Glo assay, Promega); MEG-01 cells were treated for 24
hours with LNA anti-miR-21 or anti-miR-222 or anti-
miR-148a followed by addition of fludarabine for addi-
tional 24 hours. A significant (p < 0.01) increase of cas-
pase 3/7 activity was detected for miR-21 and miR-222
(Figure 5A, B) while no difference was observed for
miR-148a (Figure 5C). We hereby concluded that the
high miR-21 and miR-222 levels may be responsible for
a weaker apoptotic effect of fludarabine in refractory
patients, while the mechanism of action of miR-148a
remains to be established.
Discussion
We analyzed the expression profile of 29 CLL patients
who were treated by fludarabine, a pivotal drug in the
modern treatment of CLL [25,26]. To better elucidate the
molecular mechanisms underlying the development of
fludarabine resistance, we investigated the miRNA
expression alterations of patients who received fludara-
bine as single agent, thus avoiding the potentially con-
founding elements that are inevitably present when
fludarabine is used in combination with other drugs.
Moreover, samples were obtained before and after first
fludarabine treatment from the same patient, making it
possible to directly evaluate the effect of the drug in vivo.
Our results revealed that many miRNAs are modu-
lated by fludarabine treatment, as shown by the 37
Table 2 MicroRNAs differentially expressed between refractory (NR) and sensitive (CR) patients before Fludarabine
treatment
PRE Treatment Differentially expressed microRNAs
microRNA p-
value
Fold change
absolute
Regulation NR/
CR
NR average
expression
CR average
expression
Chromosome Accession
hsa-miR-31 0.0091 2.21 down 1.14 2.51 chr9 MIMAT0000089
hsa-miR-125b 0.0233 1.72 down 1.17 2.02 chr11 MIMAT0000423
hsa-miR-10a 0.0234 1.85 down 1.08 1.99 chr17 MIMAT0000253
hsa-miR-181d 0.0452 1.29 down 1.49 1.92 chr19 MIMAT0002821
hsa-miR-126* 0.0462 1.18 down 1.14 1.35 chr9 MIMAT0000444
hsa-miR-21* 0.0068 3.65 up 8.13 2.23 chr17 MIMAT0004494
hsa-miR-222 0.0096 2.12 up 70.59 33.31 chrX MIMAT0000279
hsa-miR-28-3p 0.0201 3.38 up 5.04 1.49 chr3 MIMAT0004502
hsa-miR-194 0.0347 2.40 up 14.59 6.08 chr1 MIMAT0000460
hsa-miR-148a 0.0414 3.44 up 73.41 21.33 chr7 MIMAT0000243
Table 3 MicroRNAs differentially expressed between refractory (NR) and sensitive (CR) patients after Fludarabine
treatment
POST Treatment Differentially expressed microRNAs
microRNA p-
value
Fold change
absolute
Regulation NR/
CR
NR average
expression
CR average
expression
Chromosome Accession
hsa-miR-138-2* 0.0142 1.91 down 1.39 2.65 chr16 MIMAT0004596
hsa-miR-21* 0.0168 3.11 up 9.60 3.09 chr17 MIMAT0004494
hsa-miR-148a 0.0188 2.77 up 119.81 43.27 chr7 MIMAT0000243
hsa-miR-221* 0.0212 1.96 up 9.75 4.97 chrX MIMAT0004568
hsa-miR-21 0.0244 2.29 up 15,079.56 6,580.23 chr17 MIMAT0000076
hsa-miR-192 0.0266 1.95 up 35.14 18.04 chr11 MIMAT0000222
hsa-miR-194 0.0378 2.20 up 17.70 8.04 chr1 MIMAT0000460
hsa-miR-801 0.0408 1.81 up 44.94 24.83 chr1 MIMAT0004209
hsa-miR-598 0.0428 2.18 up 9.88 4.53 chr8 MIMAT0003266
hsa-miR-20a* 0.0448 1.99 up 37.27 18.77 chr13 MIMAT0004493
hsa-miR-222 0.0486 1.97 up 52.07 26.38 chrX MIMAT0000279
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Page 5 of 15Figure 2 Classification of CLL patients in accordance to miRNAs that differentiate fludarabine responders from not responders.A )
Eleven miRNAs are significantly (p < 0.05) modulated before fludarabine treatment between resistant and sensitive CLLs and were used for
sample classification; cluster analysis revealed a good separation between the two classes. (B) Expression profile after fludarabine treatment; Ten
miRNAs are differentially expressed (p < 0.05) in patients that will respond or not to chemotherapy; again, a good separation was achieved.
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Page 6 of 15miRNAs that are modulated following the treatment in
both CR and NR patients, while 23 and 30 miRNAs
were differentially modulated only in CRs or NRs,
respectively, suggesting that these two cohorts
of patients show signs of differences in the execution of
molecular pathways modulated by fludarabine.
Indeed, in an effort to elucidate the mechanisms
underlying the differential expression of these miRNAs,
we analyzed the molecular pathways modulated by flu-
darabine in sensitive and refractory CLLs that emerged
by mRNA expression analysis. The discovery that many
p53 pathway genes (i.e. CDKN1A, BBC3/PUMA, PCNA,
GADD45A) were activated in CRs but not in NRs pro-
vides further support to the notion that fludarabine
treatment of patients with CLL induces a p53-dependent
gene expression response [27] and that a defective p53
pathway in refractory CLLs, due to 17p deletions, p53
mutations and other p53-linked dysfunctions, is asso-
ciated with fludarabine resistance [4,25,26,28]. It is
therefore possible that the differential expression of
miRNAs between CR versus NR patients may be
affected by a defective p53 pathway. Interestingly, it has
been reported that miR-221/222 cluster is repressed by
p53 [29], implicating that a non-functional p53 pathway
may lead to its up-regulation, as detected in NR
patients. An example of an aberrantly expressed miRNA
influenced by p53 in fludarabine-refractory CLL has
been recently reported by Zenz and colleagues, who
observed a higher frequency of fludarabine refractory
CLLs in the group of low-expressing miR-34a, than in
similar patients with high expression of this miRNA
[30]. MiR-34a was shown to be a direct transcriptional
target of p53 [31]. Although we did not find a signifi-
cant differential expression level of miR-34a in NR
Figure 3 Quantitative RT-PCR validation for miR-222, miR148a and miR-21 in independent CLL patients. A) MiRNAs expression in a novel
cohort of not responder (NR) and complete responder (CR) patients, before fludarabine treatment, quantified by using TaqMan reverse
transcription qPCR. Each expression data is normalized on endogenous U6 RNA levels by 2
-ΔCt method. Each sample has been analyzed in
triplicate. Data are displayed using vertical scatter plot (GraphPad v.5), bars represent means ± SEM. Two-tailed t-test was used to determine the
p-values. B) Prediction of response to treatment in newly diagnosed CLL patients in accordance to a 3 miRNAs-based score. A threshold useful
to predict response to therapy was established based on miRNA relative expression. Each patient with a final score >1 was classified as
refractory.
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Page 7 of 15Table 4 Pathways significantly enriched among the genes modulated by Fludarabine in sensitive and refractory CLLs
Significant pathways in responder patients Significant pathways in non responder patients
Pathway Number
of
Entities
Matched
with
Technology
Matched
with
EntityList
pValue Number
of
Entities
Matched
with
Technology
Matched
with
EntityList
pValue
G1/S DNA Damage Checkpoints 11 2 2 5.40E-04 11 2 1 4.64E-02
Stabilization of p53 5 2 2 5.78E-04 5 2 1 5.08E-02
p53-Dependent G1 DNA Damage
Response
7 2 2 5.78E-04 7 2 1 5.08E-02
p53-Dependent G1/S DNA damage
checkpoint
7 2 2 5.78E-04 7 2 1 5.08E-02
BH3-only proteins associate with and
inactivate anti-apoptotic BCL-2
members
9 3 2 1.70E-03
p53 signaling pathway 14 11 3 1.98E-03
atm signaling pathway 17 13 3 3.31E-03 17 13 2 4.28E-02
Class I PI3K signaling events 456 181 12 4.91E-03 456 181 10 1.43E-02
Aurora A signaling 117 43 5 5.49E-03
hypoxia and p53 in the cardiovascular
system
27 16 3 6.13E-03
tumor suppressor arf inhibits ribosomal
biogenesis
27 16 3 6.13E-03
inhibition of cellular proliferation by
gleevec
21 17 3 6.67E-03 21 17 2 5.93E-02
nfkb activation by nontypeable
hemophilus influenzae
29 17 3 6.67E-03 29 17 2 5.93E-02
TRAIL signaling pathway 641 246 15 7.54E-03 641 246 15 3.24E-03
IL2 signaling events mediated by PI3K 110 33 5 7.73E-03
Activation of BH3-only proteins 13 6 2 8.12E-03
cell cycle: g2/m checkpoint 24 19 3 1.01E-02 24 19 2 8.48E-02
Signaling events mediated by HDAC
Class III
44 21 3 1.22E-02 44 21 2 8.62E-02
repression of pain sensation by the
transcriptional regulator dream
15 8 2 1.38E-02
mapkinase signaling pathway 41 39 4 1.40E-02 41 39 3 7.84E-02
rna polymerase iii transcription 10 8 2 1.47E-02
Signaling events regulated by Ret
tyrosine kinase
131 40 4 1.61E-02
Signaling by Aurora kinases 162 59 5 1.76E-02
IL2-mediated signaling events 184 64 6 1.87E-02 184 64 5 6.96E-02
Role of Calcineurin-dependent NFAT
signaling in lymphocytes
133 64 5 1.88E-02
oxidative stress induced gene
expression via nrf2
16 10 2 2.15E-02
G(s)-alpha mediated events in
glucagon signalling
5 1 1 2.33E-02
Activation of PUMA and translocation
to mitochondria
1 1 1 2.41E-02
Activation of NOXA and translocation
to mitochondria
1 1 1 2.41E-02
G2/M DNA damage checkpoint 7 1 1 2.41E-02
Intrinsic Pathway for Apoptosis 32 12 2 3.05E-02
agrin in postsynaptic differentiation 23 13 2 3.55E-02
cadmium induces dna synthesis and
proliferation in macrophages
37 13 2 3.55E-02
Plasma membrane estrogen receptor
signaling
547 217 11 3.66E-02 547 217 9 8.14E-02
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Zenz et al., in fact 3 patients with the 17p deletion
involved in this study displayed no miR-34a expression
(data not shown).
By comparing the miRNA expression profile of sensi-
tive and refractory CLLs, we have been able to identify
expression signatures that could correctly classify more
than 80% of the CR vs NR cases, either before or after
treatment. Interestingly, after validation by quantitative
PCR of the most significant miRNAs (miR-21, miR-222
and miR-148a) in an independent population, the pre-
diction of response to therapy for pre-therapy samples
was impressive: a predictive score based on miRNA
expression levels reached an overall accuracy of 100%.
This information may have important clinical implica-
tions because it might spare subsequent treatment
in patients identified as resistant during disease
progression.
MiRNAs aberrant expression may not only represent a
phenomenon able to reveal an underlying molecular
defect, such as p53 dysfunction, but it may also
represent one of the possible mechanisms responsible
for fludarabine resistance. In this study, we found that
some miRNAs, namely miR-222, miR-148a and miR-21
were differentially expressed between NR and CR CLLs
both before and after fludarabine treatment and were all
up-regulated in the NR group. These findings, not pre-
viously described in CLL, appears to be truly significant.
Indeed, miR-222 can target the cell growth suppres-
sive cyclin-dependent kinase inhibitors p27 and p57 and
the c-KIT receptor (source: Tarbase) thus promoting
cell cycle progression [23,32]. Among the recently vali-
dated targets there are the BH3-only pro-apoptotic pro-
tein BMF [33], the cell adhesion molecule ICAM-1 [34],
matrix metalloproteinase 1 (MMP1) and manganese
superoxide dismutase 2 (SOD2), which are both
involved in tongue carcinoma metastasis promotion [35]
and whose expression is frequently altered in cancer. An
higher expression of miR-222 has been associated with
poor survival in pancreatic cancer [36] and the enforced
expression of miR-221/222 improved the growth of
prostate carcinoma xenografts in mice [37]. Moreover,
Table 4: Pathways significantly enriched among the genes modulated by Fludarabine in sensitive and refractory CLLs
(Continued)
il-2 receptor beta chain in t cell
activation
42 31 3 3.77E-02
hypoxia-inducible factor in the
cardivascular system
26 14 2 4.08E-02
BMP receptor signaling 329 163 9 4.33E-02 329 163 8 4.54E-02
Class I PI3K signaling events mediated
by Akt
160 55 4 4.35E-02
rho-selective guanine exchange factor
akap13 mediates stress fiber formation
11 2 1 4.60E-02 11 2 1 4.64E-02
FasL/CD95L signaling 6 2 1 4.75E-02
alk in cardiac myocytes 20 15 2 4.93E-02 20 15 3 6.12E-03
role of mef2d in t-cell apoptosis 31 15 2 5.22E-02 31 15 4 4.38E-04
TNF receptor signaling pathway 495 213 11 7.61E-02 495 213 11 3.77E-02
integrin signaling pathway 28 21 2 9.19E-02 28 21 3 1.42E-02
FAS signaling pathway (CD95) 63 26 5 2.99E-03
endocytotic role of ndk phosphins and
dynamin
22 6 2 7.76E-03
BCR signaling pathway 94 52 5 8.63E-03
Integrins in angiogenesis 107 38 4 1.18E-02
Alkaloid biosynthesis II 45 21 3 1.81E-02
angiotensin ii mediated activation of
jnk pathway via pyk2 dependent
signaling
39 24 3 1.81E-02
t cell receptor signaling pathway 44 23 3 1.81E-02
links between pyk2 and map kinases 39 24 3 2.02E-02
dicer pathway 4 1 1 2.57E-02
AndrogenReceptor 98 93 6 3.29E-02
Osteopontin-mediated events 48 13 2 3.62E-02
TCR signaling in naïve CD8+ T cells 188 72 5 3.66E-02
fas signaling pathway (cd95) 24 14 2 4.16E-02
Ceramide signaling pathway 90 55 5 4.48E-02
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Page 9 of 15anti-sense inhibition of miR-221 could increase suscept-
ibility to gemcitabine [38].
MiR-21 up-regulation appears to be an important
mechanism of malignant transformation, since it was
found up-regulated in several types of neoplasia (see
Spizzo et al. for a list [39]); it accounts, among the
known validated targets, numerous tumors suppressor
genes, such as TPM1, PDCD4, maspin (SERPINB3) and
PTEN (source: Tarbase). New interesting targets of
miR-21 were recently identified through the validation
of proteomic results [40]. It was also correlated with
poor prognosis in tongue squamous cell carcinoma [41],
colon [42], breast [43] and pancreatic cancer [44]. Inter-
estingly, the use of the anti-miR-21 AMOs increases
susceptibility of colangiocarcinoma cells to gemcitabine
[45] and elicit a pro-apoptotic response in glioblastoma
and breast cancer cells [46,47].
Here, we report that inhibition of miR-222 and miR-
21 in the MEG-01 human cells using an anti-miRNA
oligonucleotide increases susceptibility to fludarabine, as
shown by the significant increase in caspase activity.
Our findings suggest a direct role of miR-222 and miR-
21 in conferring resistance to fludarabine chemotherapy
independently from the p53 pathway, which is dysfunc-
tional in this human cell line [48].
Less clear is the role of miR-148a. MiR-148a is up-
regulated in NR CLL patients either before and after
fludarabine treatment and it was identified also as resis-
tance predictor in pre CLLs. However, its mechanism of
action is not clear, as only two gene targets are presently
experimentally validated. One is the isoform 1 of DNA
methyltransferase 3b (DNMT3b1) [49] and the other is
the pregnane X receptor gene [50] whose repression, in
turn, reduces the expression of CYP3A4 enzyme. Our
assay revealed that its mechanism of action may not be
linked to apoptosis inhibition in resistant patients.
Therefore, its role in fludarabine resistance remains
unknown.
Conclusions
This study revealed that a characteristic miRNA
expression profile, as assessed before and soon after
start of treatment, can discriminate between fludara-
bine sensitive and fludarabine resistant CLLs. We con-
firm the importance of a defective p53 pathway in
conferring fludarabine resistance. This mechanism may
be relevant in affecting miRNA expression; however,
we suggest that an aberrant miRNA expression, i.e. up-
regulation of miR-21, miR-148a and miR-222 in NRs,
may be important in establishing resistance indepen-
dently from p53, protecting cells from apoptosis.
Indeed, inhibition of miR-21 and miR-222 may
increase sensitivity to fludarabine in vitro in a p53-
mutant cell line. The differential expression of a small
number of miRNAs can have an effect on the capabil-
ity to respond to fludarabine in CLL patients and can
be used for response prediction. Therefore our data
may help identify those elderly patients unlikely to
respond to fludarabine used as single agent and may
assist in the definition of the induction treatment in
younger patients, given the availability of non cross-
resistant drugs, such as bendamustine [51]. This infor-
mation may have an impact in the development of per-
sonalized therapeutic approaches.
Methods
Patients
Seventeen patients (training set) plus 12 patients (test
set) followed at our centre and treated with fludarabine
as single agent (25 mg/sqm/day for 5 consecutive days
for six courses given at 28 day intervals) were enrolled
in this study after obtaining informed consent. The
training set patients received fludarabine as first line
treatment in 4 cases and as second line treatment after
chlorambucil in 13 cases. All the patients had typical
morphologic features (i.e. majority of small lymphocytes
with clumped chromatin and inconspicuous nucleoli)
and a high immunophenotypic score (i.e. CD5/CD19+,
C D 2 3 + ,C D 2 2w e a kp o s i t i v e ,s u r f a c ei m m u n o g l o b u l i n
weak+, FMC7-), consistent with an unequivocal diagno-
sis of CLL. Cytogenetic and fluorescence in situ hybridi-
zation studies were performed as previously described
[52] as part of the diagnostic workup before treatment.
Response to treatment was defined according to NCI
criteria [53] and patients were divided in two groups, i.e.
those attaining a clinical response (CR) including partial
and complete responders and those who did not
respond to treatment (NR).
For miRNA/mRNA expression studies, peripheral
blood (PB) lymphocytes were separated to a >97% as
previously described [54]. In each patient of the training
cohort, cells were collected one day before the start of
the first course of fludarabine and on day 5 of treat-
ment. In the 12 patients constituting the test set, cells
were collected one day before treatment start. RNA was
isolated using Trizol LS Reagent (Invitrogen) according
to manufacturer’s instructions. Sample quality was
assessed by Agilent 2100 Bioanalyzer (Agilent
Technologies).
Human miRNA/mRNA expression detection
MiRNA expression was investigated using the Agilent
Human miRNA microarray v.2 (#G4470B, Agilent
Technologies). This microarray consists of 60-mer
DNA probes synthesized in situ and contains 15,000
features which represent 723 human miRNAs, sourced
from the Sanger miRBASE database (Release 10.1).
mRNA expression was detected using thee Agilent
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Page 10 of 15Figure 4 Differential expression of p53-pathway genes in sensitive and refractory CLLs. (A) Cellular representation of BioCarta p53
signaling pathway. Genes involved in p53 pathway were colored in accordance to microarray expression data for post CLLs normalized on
matched pre samples. Average expression in CR patients is on the right part of the colorbar, NR patients on the left part. Genes like p21,
GADD45A, PCNA are up-modulated only in sensitive CLLs. (B) Average expression of all the genes involved in p53 pathways (cell cycle control
and apoptosis) in pre/post CR and pre/post NR groups. Puma/BBC3 gene is induced only in sensitive CLLs.
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Page 11 of 15Figure 5 Impact of anti-miRNAs on MEG-01 fludarabine sensitivity. Caspase 3/7 activity after anti-miR-21, 222, 148a treatment of MEG-01
cells, in absence or presence of fludarabine (1 μM). LNA-anti-miR-21 and anti-miR-222, but not anti-miR-148a, were able to induce increase
apoptosis in MEG-01 cells, which harbor a mutant p53 protein. The inhibition of miR-21 and miR-222 sensitizes the cells to fludarabine action,
leading to an increased caspase activation when fludarabine 1 μM is added after 24 hours.
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Page 12 of 15whole human genome oligo microarray (#G4112F, Agi-
lent Technologies). This microarray consists of 60-mer
DNA probes synthesized in situ, which represent
41,000 unique human transcripts. About 500 ngs of
total RNA were employed in each experiment. RNA
labeling and hybridization were performed in accor-
dance to manufacturer’s indications. Agilent scanner
and the Feature Extraction 10.5 software (Agilent
Technologies) were used to obtain the microarray raw-
data.
Microarray data analysis
Microarray results were analyzed by using the Gene-
Spring GX 10 software (Agilent Technologies). Data
transformation was applied to set all the negative raw
values at 1.0, followed by a Quantile normalization
and a log2 transformation. Filters on gene expression
were used to keep only the miRNAs/mRNA expressed
in at least one sample (flagged as P). Then, samples
were grouped in accordance to treatment (pre and
post fludarabine) and response to treatment (NR and
CR). Differentially expressed genes were selected as
having a n-fold expression difference between their
geometrical mean among the groups of interest and a
statistically significant p-value (<0.05) by Welch t-test
statistic. For gene expression statistical analysis, the
Benjamini and Hoechberg correction for false posi-
tives reduction was used. Differentially expressed
genes were employed in Cluster Analysis, using the
Manhattan correlation as a measure of similarity and
the complete linkage rule for genes and samples clus-
terization. The identification of mRNAs modulated
after fludarabine, in matched samples, was done using
the filter on 0-10th percentile in at least 75% of
patients, for the miRNAs down-modulated by treat-
ment, and a filter on 90-100th percentile in at least
75% of patients, for the miRNAs up-modulated by
treatment. All Microarray data were submitted to
ArrayExpress, accession number to be received.
Pathway Analysis
The Pathway Enrichment Analysis was performed using
GeneSpring GX tools, based on KEGG, BioCarta, Bio-
pax, Cellmap and NCI-Nature databases.
Quantitative RT-PCR
Quantitative Real time RT-PCR (qRT-PCR). Mature
miRNAs expression was evaluated by Taqman
MiRNA assays (Applied Biosystem) specific for miR-
21, miR-222, miR-148a and RNU6B as reference gene
according to the manufacturer’s protocol. Briefly,
5 ng of total RNA was reverse transcribed using the
specific looped primer; real time quantitative PCR
was conducted using the standard Taqman MiRNA
assay protocol on a Biorad-Chromo4 thermal cycler.
Each sample was analyzed in triplicate. The level of
miRNA was measured using Ct (threshold cycle). The
amount of target, normalized on U6 RNA amount,
was calculated using 2
-ΔCt (Comparative Ct) method
as implemented by Biorad Genex macro for excel pro-
gram. Significance in qRT-PCR results was deter-
mined by t-test. Box plot graphs were created using
Microsoft Excel program.
Calculation of a predictive score
For miR-21, miR-222 and miR-148a, a CR vs NR thresh-
old value was determined by calculating and selecting
the first integer number above the 98th percentile of
expression values (as described in quantitative RT-PCR
method) distribution in CR group. For each miRNA, a
score of 0 was assigned when expression was below the
threshold and a score of 1 when above. The sum of
these scores for the three miRNAs was used to assign
patients to one of two classes (CR or NR): for scores 0
to 1, the patient was predicted as CR; for scores 2 to 3,
the patient was predicted as NR.
Cell lines and transfection
MEG01 (ATCC number CRL-2021), cell line was cul-
tured with RPMI-1640 medium with 10% fetal bovine
serum and 0.1% gentamicin. LNA knockdown probe
anti-miR-2 and Scramble-miR control were from Exi-
qon, Negative control, anti-miR-148a and anti-miR-222
were from Ambion. Transfection of oligos was carried
out with lipofectamine 2000 (Invitrogen) and Optimem
reduced serum medium (Invitrogen) in accordance with
manufacturer’s procedure.
Caspase 3/7 assays
Caspase 3/7 activity assay was performed on MEG01
cell line. Cells were cultured in 96-well plates the day
before LNA-anti-miR-21, anti-miR-222, anti-miR-
148a and control transfections (50 nmol). After
24 hours from transfection, cells were treated with
fludarabine at the concentrations of 0 and 1 μMf o r
additional 24 hours. The assay was performed in
accordance with manufacturer’s protocol (Promega,
Caspase-Glo 3/7 assay). Each experiment was per-
formed in triplicate.
List of abbreviations used
CLL: Chronic Lymphocytic Leukemia; miR or miRNA:
microRNA; LNA: Locked nucleic acid; RT-qPCR:
reverse transcription-quantitative polymerase chain reac-
tion; CR: clinical response (complete + partial respon-
der); NR: not responder.
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Additional file 1: Table S1. MicroRNAs modulated by fludarabine in
sensitive and refractory CLL patients
Additional file 2: Table S2. MicroRNAs modulated by fludarabine in
either sensitive or refractory CLL patients
Additional file 3: Figure S1. Quantitative RT-PCR validation for miR-222,
miR148a and miR-21 in CLL patients. MiRNAs expression in Not
Responder (NR) and Complete Responder (CR) patients, after fludarabine
treatment, was quantified using TaqMan Real-time RT-PCR. Every
expression data was normalized on endogenous U6 RNA levels by 2
-ΔCt
method. Each sample was analyzed in triplicate. Data are displayed using
vertical scatter plot (GraphPad v.5), bars represent means ± SEM. Two-
tailed t-test was used to determine the p-values.
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